2016 Gastric Cancer Pipeline Market Covering 127 Companies
PUNE, India, May 25, 2016 /PRNewswire-iReach/ -- Gastric Cancer Pipeline Market Companies Involved in Therapeutics Development are AB Science SA, AbbVie Inc., AbGenomics International, Inc., ADC Therapeutics Sarl, Advaxis, Inc., Advenchen Laboratories, LLC, Agenus, Inc., Ambrx, Inc., Amgen Inc., arGEN-X BV, Aslan Pharmaceuticals Pte. Ltd., Astellas Pharma Inc., AstraZeneca Plc, Atara Biotherapeutics, Inc., Athenex, Inc., Azaya Therapeutics, Inc., Basilea Pharmaceutica AG, Bayer AG, BeiGene, Ltd., Betta Pharmaceuticals Co. Ltd., Bionovis SA, Boehringer Ingelheim GmbH, Boston Biomedical, Inc., Bristol-Myers Squibb Company, Celgene Corporation, Celldex Therapeutics, Inc., Cellectar Biosciences, Inc., Celltrion, Inc., Celon Pharma Sp. z o.o., Cerulean Pharma, Inc., Chipscreen Biosciences Ltd, Chugai Pharmaceutical Co., Ltd., Compliment Corporation, Curaxys, S.L., DAE HWA Pharmaceutical Co., Ltd., Daiichi Sankyo Company, Limited, Deciphera Pharmaceuticals, LLC, Dr. Reddy's Laboratories Limited, Eddingpharm, EirGenix Inc., Eli Lilly and Company, Esperance Pharmaceuticals, Inc., Exelixis, Inc., F. Hoffmann-La Roche Ltd., Five Prime Therapeutics, Inc., Frost Biologic, Inc., Galena Biopharma, Inc., Genelux Corporation, Genentech, Inc., Gilead Sciences, Inc., GlaxoSmithKline Plc, GlycoNex Inc., Glycotope GmbH, Green Cross Corporation, Halozyme Therapeutics, Inc., Hanmi Pharmaceuticals, Co. Ltd., Hetero Drugs Limited, Horizon Pharma Plc, Hutchison MediPharma Limited, Ignyta, Inc., Immunomedics, Inc., Incyte Corporation, Innovent Biologics, Inc., INSYS Therapeutics, Inc., ISU ABXIS Co.,Ltd., Jiangsu Hengrui Medicine Co., Ltd., Jiangsu Kanion Pharmaceutical Co., Ltd., Johnson & Johnson, KaloBios Pharmaceuticals, Inc., Karyopharm Therapeutics, Inc., Kolltan Pharmaceuticals, Inc., Kuhnil Pharmaceutical Co., Ltd., Kyowa Hakko Kirin Co., Ltd., LegoChem Biosciences, Inc, Les Laboratoires Servier SAS, MacroGenics, Inc., Mebiopharm Co., Ltd., MedImmune, LLC, Medivation, Inc., Merck & Co., Inc., Merck KGaA, Merrimack Pharmaceuticals, Inc., Mersana Therapeutics, Inc., Merus B.V., Millennium Pharmaceuticals, Inc., Molecular Targeting Technologies, Inc., MolMed S.p.A., NanoCarrier Co., Ltd., Novartis AG, OBI Pharma, Inc., Omnitura Therapeutics Inc., Oncobiologics, Inc., Oncolys BioPharma Inc., Oncolytics Biotech Inc., OncoTherapy Science, Inc., Ono Pharmaceutical Co., Ltd., Panacea Biotec Limited, Patrys Limited, Pfizer Inc., Pharma Mar, S.A., Pharmacyclics, Inc., Puma Biotechnology, Inc., Rexahn Pharmaceuticals, Inc., Richter Gedeon Nyrt., Sanofi, Sareum Holdings Plc, Sequella, Inc., Shanghai Henlius Biotech Co., Ltd., Shionogi & Co., Ltd., Sihuan Pharmaceutical Holdings Group Ltd., Simcere Pharmaceutical Group, Sorrento Therapeutics, Inc., Spectrum Pharmaceuticals, Inc., Sunesis Pharmaceuticals, Inc., Supratek Pharma Inc., Synovo GmbH, Synta Pharmaceuticals Corp., Synthon Holdings BV, Taiho Pharmaceutical Co., Ltd., Takeda Pharmaceutical Company Limited, Takis S.r.l., Tara Immuno-Oncology Therapeutics LLC, TG Therapeutics, Inc., Transgene SA, Vaxon Biotech, ViiV Healthcare Limited and Zymeworks Inc.
Photo - http://photos.prnewswire.com/prnh/20160525/371896
The report helps in identifying and tracking emerging players in the market and their portfolios, enhances decision making capabilities and helps to create effective counter strategies to gain competitive advantage.
Note*: Certain sections in the report may be removed or altered based on the availability and relevance of data.
Inquire more about this research report at http://www.rnrmarketresearch.com/contacts/inquire-before-buying?rname=582457
The report provides comprehensive information on the therapeutics under development for Gastric Cancer, complete with analysis by stage of development, drug target, mechanism of action (MoA), route of administration (RoA) and molecule type. The report also covers the descriptive pharmacological action of the therapeutics, its complete research and development history and latest news and press releases. Additionally, the report provides an overview of key players involved in therapeutic development for Gastric Cancer and features dormant and discontinued projects.
- The report provides a snapshot of the global therapeutic landscape of Gastric Cancer
- The report reviews pipeline therapeutics for Gastric Cancer by companies and universities/research institutes based on information derived from company and industry-specific sources
- The report covers pipeline products based on various stages of development ranging from pre-registration till discovery and undisclosed stages
- The report features descriptive drug profiles for the pipeline products which includes, product description, descriptive MoA, R&D brief, licensing and collaboration details & other developmental activities
- The report reviews key players involved Gastric Cancer therapeutics and enlists all their major and minor projects
- The report assesses Gastric Cancer therapeutics based on drug target, mechanism of action (MoA), route of administration (RoA) and molecule type
- The report summarizes all the dormant and discontinued pipeline projects
- The report reviews latest news related to pipeline therapeutics for Gastric Cancer
Complete research report of 962 pages with TOC is available at http://www.rnrmarketresearch.com/gastric-cancer-pipeline-review-h1-2016-market-report.html
Reasons to buy
- Gain strategically significant competitor information, analysis, and insights to formulate effective R&D strategies
- Identify emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage
- Identify and understand important and diverse types of therapeutics under development for Gastric Cancer
- Identify potential new clients or partners in the target demographic
- Develop strategic initiatives by understanding the focus areas of leading companies
- Plan mergers and acquisitions effectively by identifying key players and it's most promising pipeline therapeutics
- Devise corrective measures for pipeline projects by understanding Gastric Cancer pipeline depth and focus of Indication therapeutics
- Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope
- Modify the therapeutic portfolio by identifying discontinued projects and understanding the factors that drove them from pipeline
Media Contact: Ritesh Tiwari, RnR Market Research, + 1 888 391 5441, firstname.lastname@example.org
News distributed by PR Newswire iReach: https://ireach.prnewswire.com
SOURCE RnR Market Research